Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab versus Fumaderm in adults with moderate to severe plaque psoriasis
2014-005258-20Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab, Fumaderm in plaque psoriasis, psoriasis, sponsored by Novartis. Started Feb 2015; status: completed.
02
Drugs
secukinumabFumaderm
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2014-005258-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005258-20.